Skip to Navigation Skip to Content
  • Diagnostics
  • About Abbott
Abbott Menu Location
Alere is now Abbott
  • You are here
  • Location
  • iconAbout

    About

    Abbott is a world leader in rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology.

    Read More
    • Partnerships
    • Experience POCT Stories
    • Events
    • Abbott Locations
    • News Archive
    • Investors

      Investors

      Through our mission, we aim to improve clinical outcomes, reduce healthcare costs and deliver earnings growth to our investors.

      Read More Back
    • Contact Details
    • Contacts (Africa)

      Contacts (Africa)

      Each territory in Africa is assigned to a specific Alere Business Manager who will have the responsibility to support you for all the essential commercial activities

      Read More Back
      • Africa Business Development and Support Services
      • EABU – English East Africa
      • EWBU – English West Africa
      • NFBU & CABU
      • SABU – South Africa
      • ZABU - Southern Africa
    • Local Support

      Local Support

      We are a global leader in the field of rapid diagnostic tests designed to improve the quality of patient care. Specific product lines include tests for rapid and early diagnosis in the fields of cardiovascular, infectious diseases, women's health, drugs of abuse and oncology.

      Read More Back
      • Conferences
      • Download Documents
      • Newsletters
    • Alere™ i Hospital Experience
  • iconViewpoints

    Viewpoints

    Point-of-care diagnostics is a growing and dynamic industry helping to improve clinical and economic outcomes globally. Discover a variety of expert viewpoints on new innovations, insights, and impacts that are shaping the future of diagnostics around the world.

    Read More
    • What does the NHTSA data mean for the future of roadside testing?
    • Don't Take that Antibiotic. You Might Get. . .Fat?
    • Malaria - Plasmodium Knowlesi: The New Threat
    • What's the Value of Molecular Testing at the POC?
    • Considerations for Setting a THC Cut-Off to Detect Cannabis Use in Oral Fluid Screening
    • The Importance of Evidence-Based Medicine in Point-of-Care Testing
    • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis
    • Call for Action in Acute Heart Failure: "Time is Life!"
    • Allaying Employees' Concerns About Workplace Drug Testing
    • Antimicrobial Resistance: Getting Straight to the Point!
    • Overcoming the screening challenges of new psychoactive substances
    • Comprehensive Diabetes Patient Care Program Yields Measureable Results
    • Fighting the Growing Threat of Antimicrobial Resistance
    • Zika Virus: A Growing Public Health Threat
    • Progress in Total Analytical Error Reduction
    • Strengthening Referrals and Linkages in Swaziland
    • Designer Stimulant Testing: A Fast Moving Target
    • Left Behind in the Global Response to HIV
    • Eliminating Malaria in India
    • New Guidance for Physicians for Diagnosing C. diff
    • Clinicians Gather to Encourage Point-of-Care Testing in Latin America
    • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance
    • RSV. It's Not Just for Kids Anymore!
    • Improving Type 2 Diabetes and Hypertension Services in Honduras
    • The Global Threat of Drug-Resistant Tuberculosis - Are We Doing Enough?
    • Workplace Policies for Prescription Drugs
    • Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands
    • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda
    • The Benefits of Pre-Employment Drug Testing
    • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management
    • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
    • "This Respiratory Season, FDA's Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes"
    • Bringing "Health on Wheels" to At-Risk Teens in Cape Town
    • The Value of Random Drug Testing
  • iconProducts & Services

    Products & Services

    Abbott products give providers, physicians and patients access to the right information at the right time.

    Read More
    • Explore Product Lookup
    • Solutions
    • Cardiometabolic

      Cardiometabolic

      Our products and services include tests to assist in the diagnosis and management of many cardiometabolic factors and conditions.

      Read More Back
      • Blood Gases
      • Coronary Heart Disease/ACS
      • Diabetes
      • Dyslipidemia
      • Heart Failure
      • Hyperglycemia
      • Oral Anticoagulation
      • Shortness of Breath
      • VTE
      • Patient Health Monitoring
    • Infectious Disease

      Infectious Disease

      Our products and services include tests to assist in the diagnosis and management of many infectious diseases.

      Read More Back
      • C. difficile
      • Cryptosporidiosis
      • Dengue Fever
      • E. coli
      • Enterics
      • Epstein Barr Virus (EBV)
      • GI Parasites
      • Hepatitis
      • Herpes Simplex Virus
      • HIV
      • Intestinal Inflammation
      • Legionnaire's Disease
      • Leptospira
      • Influenza (Flu)
      • Malaria
      • Mononucleosis
      • MRSA
      • Pneumonia
      • Ross River/Barmah Forest
      • RSV
      • Rubella
      • S. aureus
      • Strep A pharyngitis
      • Streptococcus pneumoniae
      • Syphilis
      • C-reactive Protein Diagnostic Tests
      • Tuberculosis
      • Other Infectious Disease
    • Toxicology

      Toxicology

      Broad drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents.

      Read More Back
      • Employers
      • Government
      • Hospitals
      • OEM
      • Medication Monitoring
      • Roadside Drug Testing
    • Toxicology Products & Services

      Toxicology Products & Services

      Alere™ Toxicology offers drug testing products and services that are used in a multitude of settings such as hospitals, clinics, physician offices, criminal justice, workplace, rehabilitation, occupational health clinics, and home testing.

      Read More Back
      • Laboratory Drug Screen
      • Oral Fluid Drug Test
      • Urine Drug Test
    • Other

      Other

      Our innovative diagnostics provide reliable and actionable information that enables informed decision-making by healthcare professionals at the point-of-care.

      Read More Back
      • Clinical Immunology
      • Oncology
      • POCT Data Management Platform
      • Women's Health
    • Browse by Brand

      Browse by Brand

      Our rapid diagnostic products are changing how healthcare is delivered-extending diagnosis and health management from the lab, doctor's office and hospital into people's homes.

      Read More Back
      • Alere Afinion
      • Alere Actim
      • Alere BinaxNOW
      • Alere Cholestech LDX
      • Alere Determine
      • Alere hCG
      • Alere i
      • Alere Influenza A & B Test
      • Alere NMP22
      • Alere PBP2a
      • Alere Pima CD4
      • Alere q
      • Alere TestPack
      • Alere Toxicology
      • Alere Triage
      • AegisPOC
      • Clearview
      • epoc
      • NHS Health Checks
      • iCup
      • NycoCard
      • Standard Diagnostics
      • TECHLAB
      • Wampole
      • Additional Brands
    • NHS Health Checks
    • For Patients
  • iconSupport

    Support

    Connect with us.

    Read More
    • Contact Us

      Contact Us

      Contact us for sales assistance, technical support or further information.

      Read More Back
    • Product Document Search
    • Product Document Search
    • Product Demos
    • Terms of Trade
    • IQCP Support Resources

      IQCP Support Resources

      The Clinical Laboratory Improvement Amendments (CLIA) program recently introduced the Individualized Quality Control Plan (IQCP) as a new quality control option for nonwaived testing. We are pleased to provide you with materials to support your IQCPs.

      Read More Back
    • Alere Instrument Warranty Registration
    • Laboratory Test Support Resources
    • HIPAA & Patient Information
    • Product Software Download
  • iconCareers

    Careers

    Alere Inc. is a major global developer, manufacturer and marketer of advanced medical diagnostic products.

    Read More
    • Open Jobs: Africa
    • Open Jobs: Asia Pacific
    • Open Jobs: Europe & Middle East
    • Open Jobs: Latin America
    • Open Jobs: North America
  • iconContact Us
  • iconFrançais
  • iconPortuguês
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube

Welcome.

Please select your country.

All Regions
  • Global
  • United States
  • Africa
  • Argentina
  • Australia
  • België / Belgique
  • Brasil
  • Canada
  • Česká republika
  • 中华人民共和国
  • Colombia
  • Denmark
  • Deutschland
  • España
  • France
  • India
  • Indonesia
  • Ireland
  • Italia
  • Japan
  • 대한민국
  • Malaysia
  • Nederland
  • New Zealand
  • Norge
  • Österreich
  • Portugal
  • Schweiz / Suisse
  • Suomi
  • Sverige
  • 臺灣
  • United Kingdom
  • Home
    • Viewpoints
    • What does the NHTSA data mean for the future of roadside testing?
    • Don't Take that Antibiotic. You Might Get. . .Fat?
    • Malaria - Plasmodium Knowlesi: The New Threat
    • What's the Value of Molecular Testing at the POC?
    • Considerations for Setting a THC Cut-Off to Detect Cannabis Use in Oral Fluid Screening
    • The Importance of Evidence-Based Medicine in Point-of-Care Testing
    • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis
    • Call for Action in Acute Heart Failure: "Time is Life!"
    • Allaying Employees' Concerns About Workplace Drug Testing
    • Antimicrobial Resistance: Getting Straight to the Point!
    • Overcoming the screening challenges of new psychoactive substances
    • Comprehensive Diabetes Patient Care Program Yields Measureable Results
    • Fighting the Growing Threat of Antimicrobial Resistance
    • Zika Virus: A Growing Public Health Threat
    • Progress in Total Analytical Error Reduction
    • Strengthening Referrals and Linkages in Swaziland
    • Designer Stimulant Testing: A Fast Moving Target
    • Left Behind in the Global Response to HIV
    • Eliminating Malaria in India
    • New Guidance for Physicians for Diagnosing C. diff
    • Clinicians Gather to Encourage Point-of-Care Testing in Latin America
    • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance
    • RSV. It's Not Just for Kids Anymore!
    • Improving Type 2 Diabetes and Hypertension Services in Honduras
    • The Global Threat of Drug-Resistant Tuberculosis - Are We Doing Enough?
    • Workplace Policies for Prescription Drugs
    • Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands
    • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda
    • The Benefits of Pre-Employment Drug Testing
    • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management
    • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
    • "This Respiratory Season, FDA's Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes"
    • Bringing "Health on Wheels" to At-Risk Teens in Cape Town
    • The Value of Random Drug Testing
  • Home
  • Viewpoints
Share
  • Facebook
  • Twitter
  • Google+
  • linkedIn
  • Pinterest
  • Email
Viewpoints

Viewpoints

impact 08/12/16

Antimicrobial Resistance: Getting Straight to the Point! about Rapid CRP Testing in Primary Care

author
Dr. Jayne Ellis
Medical Director Western Europe & Nordics, Alere
Antimicrobial Resistance: Getting Straight to the Point! about Rapid CRP Testing in Primary Care

Antimicrobial resistance (AMR) is a global healthcare and economic problem. Experts believe that we are on the cusp of a “post-antibiotic era,” in which once treatable diseases become much more serious, and even deadly, if significant action is not taken quickly and on a global level.1

The latest data shows that up to 50,000 lives are lost annually due to antibiotic-resistant infections in Europe and the U.S. and at least 700,000 people die globally each year due to drug-resistant illnesses.1 Without effective action, it has been estimated that AMR could kill up to 10 million people a year by 2050, with a cumulative cost to the global economy of £70 trillion.1 This would mean the death of one person every three seconds from AMR.

Of the strategies proposed to deal with this threat, rapid diagnostic tests are increasingly recognised as a crucial component for optimising the prescribing of antibiotics and reducing their use.1 There is a strong relationship between high prescribing and emerging resistance (Figure 1),2 and the majority of antibiotics are prescribed in primary care.3

In the Nordic countries and the Netherlands, point-of- care C-reactive protein (CRP) testing has been used for a number of years to help guide who needs an antibiotic and who does not for respiratory tract infections (RTIs). RTIs are one of the major reasons people attend primary care (especially in winter) and often seeking an antibiotic prescription.4 However, antibiotic prescriptions for RTIs are often inappropriate because most RTIs are viral.4 There is limited evidence to support the use of antibiotics in acute bronchitis, sore throat, sinusitis and otitis media.4

Use of point-of-care CRP testing in primary care has been shown to significantly reduce antibiotic prescribing by up to 42% in lower respiratory tract infections.2 CRP is a biomarker in blood which indicates the presence of inflammation; the amount of CRP in the body gives an indication of the severity of an RTI infection. Low levels of CRP are indicative of viral or self-limiting bacterial infections; high levels indicate serious infection.4 CRP testing must be included in the consultation to help antibiotic decision-making.

In the UK, Alere has been working with academics and healthcare professionals who support point-of-care CRP testing to enable adoption of the test in primary care. This led to the publication of the Straight to the Point! Consensus report,5 which summarises compelling evidence that point-of-care CRP testing helps differentiate self-limiting RTIs from more serious infections requiring antibiotics. Launched in June 2015, the report calls on healthcare policy makers, payers and general practitioners (GPs) to enable policies and support for uptake of point-of-care CRP testing in primary care.

Since the start of this high-level discussion, the National Institute of Health and Care Excellence (NICE) has included point-of-care CRP testing in the Pneumonia clinical guidelines6 and the Antimicrobial Stewardship guidelines.7 In addition, Public Health England (PHE),8 and the Royal College of General Practitioners (RCGP) TARGET Toolkit9 now include point-of-care CRP testing for RTI consultation.

In order to build awareness, a drop-in session was conducted in the Houses of Parliament in May 2016, where over 20 members of Parliament were tested for CRP (Figure 2). There is also potential for pharmacies to deliver the CRP test service for the GP and patients.

Rapid diagnostic tests are high on the patient safety agenda, but require widespread uptake and investment. They can improve diagnostic precision in the GP consultation, increase patient education, are cost effective, and importantly, reduce antibiotic prescribing.

The point-of-care CRP test is not the perfect bacterial/viral test, but it can and is making a significant contribution to the reduction in antibacterial use in primary care. Rapid diagnostic tests are high on the patient safety agenda, but require widespread uptake and investment. They can improve diagnostic precision in the GP consultation, increase patient education, are cost-effective, and importantly, reduce antibiotic prescribing.

In the recent report on Antimicrobial Resistance, Lord Jim O’Neill highlighted “we need to encourage more innovation and, importantly, must ensure that useful [diagnostic] products are used. I call on the governments of the richest countries to mandate now that by 2020, all antibiotic prescriptions will need to be informed by up-to-date surveillance information and a rapid diagnostic test wherever one exists.”1

References
  1. Review on Antimicrobial Resistance: Tackling drug-resistant infections globally: Final report and recommendations. May 2016. http://amr-review.org/Publications.
  2. Goosens, H. et al (2005) Lancet 365: 579-587.
  3. European Centre for Disease Prevention and Control. http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?List=8db7286c-fe2d-476c-9133-18ff4cb1b568&ID=1071.
  4. Cooke J, et al. (2015) BMJ Open Resp Res 2:e000086.  
  5. Straight to the Point! Consensus Report, 2015. http://www.patients-association.org.uk/wp-content/uploads/2015/06/straight-to-the-point.pdf.
  6. NICE Pneumonia Clinical Guideline CG 191.  https://www.nice.org.uk/guidance/cg191.
  7. NICE Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NG 15. https://www.nice.org.uk/guidance/ng15.
  8. Public Health England Public Health England: Health Matters. https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance.
  9. RCGP Target Toolkit http://www.rcgp.org.uk/clinical-and-research/toolkits/target-antibiotics-toolkit.aspx.
  • Antimicrobial resistance
  • CRP
  • Rapid diagnostics
  • Improved patient outcomes
  • Email
  • Facebook
  • Twitter
  • linkedIn
  • Google+
  • Print

Related Articles

  • View all
  • Hide all
  • This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes

    insight

    This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes

    View Now

    October 12, 2017

  • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda

    impact

    Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda

    View Now

    May 31, 2017

  • The Global Threat of Drug-Resistant Tuberculosis – Are We Doing Enough?

    insight

    The Global Threat of Drug-Resistant Tuberculosis – Are We Doing Enough?

    View Now

    March 20, 2017

  • RSV. It’s Not Just for Kids Anymore!

    innovation

    RSV. It’s Not Just for Kids Anymore!

    View Now

    March 20, 2017

  • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance

    insight

    Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance

    View Now

    March 20, 2017

  • Clinicians Gather to Encourage Point-of-Care Testing in Latin America

    impact

    Clinicians Gather to Encourage Point-of-Care Testing in Latin America

    View Now

    January 23, 2017

  • New Guidance for Physicians for Accurately Diagnosing <em>C. difficile</em> Infection

    insight

    New Guidance for Physicians for Accurately Diagnosing C. difficile Infection

    View Now

    January 23, 2017

  • Eliminating Malaria in India

    impact

    Eliminating Malaria in India

    View Now

    January 23, 2017

  • Left Behind in the Global Response to HIV

    insight

    Left Behind in the Global Response to HIV

    View Now

    November 14, 2016

  • Strengthening Referrals and Linkages in Swaziland

    impact

    Strengthening Referrals and Linkages in Swaziland

    View Now

    November 14, 2016

  • Reflecting on Progress in Total Analytical Error Reduction in Diagnostic Tests

    innovation

    Reflecting on Progress in Total Analytical Error Reduction in Diagnostic Tests

    View Now

    September 29, 2016

  • Zika Virus: A Growing Public Health Threat

    insight

    Zika Virus: A Growing Public Health Threat

    View Now

    September 29, 2016

  • Fighting the Growing Threat of Antimicrobial Resistance

    impact

    Fighting the Growing Threat of Antimicrobial Resistance

    View Now

    September 29, 2016

  • Comprehensive Diabetes Patient Care Program Yields Measureable Results

    impact

    Comprehensive Diabetes Patient Care Program Yields Measureable Results

    View Now

    08/12/16

  • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis

    impact

    African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis

    View Now

    06/30/16

  • Molecular 101. What’s the Value of Molecular Testing at the POC?

    insight

    Molecular 101. What’s the Value of Molecular Testing at the POC?

    View Now

    06/30/16

  • Malaria - Plasmodium Knowlesi: The New Threat

    insight

    Malaria - Plasmodium Knowlesi: The New Threat

    View Now

    06/30/16

  • Don’t Take that Antibiotic. You Might Get... Fat? The Overuse of Antibiotics Meets the Science of Healthy Microbiomes

    insight

    Don’t Take that Antibiotic. You Might Get... Fat? The Overuse of Antibiotics Meets the Science of Healthy Microbiomes

    View Now

    06/30/16

 

Select a Topic

  • Insight
  • Innovation
  • Impact

Featured Articles:

  • The Value of Random Drug Testing
  • Bringing “Health on Wheels” to At-risk Teens in Cape Town
  • This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes
  • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
  • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management
  • The Benefits of Pre-Employment Drug Testing

Sign Up for Email Updates




Please enter valid email address.

Please enter correct answer.

Thank you for signing up.

  • About
    • Partnerships
    • Experience POCT Stories
    • Events
    • Abbott Locations
    • News Archive
    • Contact Details
    • Contacts (Africa)
    • Local Support
    • Alere™ i Hospital Experience
  • Viewpoints
  • Products & Services
    • Solutions
    • Cardiometabolic
    • Infectious Disease
    • Toxicology
    • Toxicology Products & Services
    • Other
    • Browse by Brand
    • NHS Health Checks
    • For Patients
  • Support
    • Contact Us
    • Product Document Search
    • Product Document Search
    • Product Demos
    • Terms of Trade
    • IQCP Support Resources
    • Alere Instrument Warranty Registration
    • Laboratory Test Support Resources
    • HIPAA & Patient Information
    • Product Software Download

Explore more with Abbott

  • About Abbott
  • Abbott Diagnostics
  • Alere-i.com
  • TestTargetTreat.com
  • AlereToxicology.com
  • PTINR.com
  • AlereToxicology.co.uk
  • AlereHealthcareConnections.com
  • eScreen.com
  • AlereCoag.com
  • Contact Us
  • Product Document Search
  • Careers

©2018 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model.

California Transparency in Supply Chains Act | Declaration for California Compliance Law

Abbott Rapid Diagnostics - A Leader in Rapid Point-of-Care Diagnostics.

Based on your current location, the content on this page may not be relevant for your country.
Please click here to return to the homepage. Alternatively, click the X button to acknowledge and proceed.
Close